The Real Price of Admission for CVS Health Stock

The stock’s current valuation looks steep, but for a patient holder, the price tag on future earnings tells a very different story.

At a glance, CVS Health (CVS) stock looks expensive. Trading at about $105.91, its trailing twelve months price-to-earnings ratio sits at a lofty 46.0. For many investors, that’s where the analysis stops.

But that’s the price on last year’s performance. Look two years out, and the picture changes completely. On the earnings analysts expect by 2027, that same $105.91 share price represents a multiple of just 12.6 times. That’s a 73% discount from today’s trailing multiple, a compression that happens on its own if the company’s earnings grow into the price. For a patient holder, you are effectively buying the business two years from now at that far lower valuation.

Is the Growth Credible?

The honest question is never the price tag; it is whether the growth that produces this discount actually arrives. Here, the consensus forecast seems grounded. Analysts see revenue growing about 2.2% a year. That’s actually well below the 7.6% the company delivered over the last twelve months and the 6.2% it posted in the most recent quarter. If recent momentum holds, the earnings estimates could prove conservative.

Crucially, the consensus forecast for this year’s earnings of about $7.43 per share lands squarely inside management’s own raised guidance of $7.30 to $7.50. When the company’s outlook corroborates the consensus, it lends the forecast more weight. The engine for this is the ongoing margin recovery in its Health Care Benefits segment, where management noted on its latest call that they “drove over $1 billion of year-over-year AOI improvement at Aetna.” This is supported by initiatives like accelerating biosimilar adoption for major drugs, which management says follows a “proven playbook.”

And CVS Health is far from alone: which 10 S&P 500 stocks carry the biggest hidden forward discount? Our rankings sort the entire index by how little you are really paying for each name’s growth once the out-year earnings land.

The Price of Uncertainty

Of course, a stock priced for growth can be volatile when sentiment shifts. In past market shocks, the stock has fallen as much as 39% from its peak. The forward discount rewards patience, but it doesn’t eliminate risk, particularly as the company navigates challenges like Medicare Advantage reimbursement rates that management deems “insufficient to offset underlying medical cost trends.”

The Payoff for Patience

This is where it’s critical to distinguish the safety from the reward. If the stock price never moves, by 2027 you would simply own a company trading at 12.6 times earnings. That compression is your margin of safety; it proves you didn’t overpay, but it isn’t a gain. The actual reward comes from price appreciation, which requires the market to keep paying a richer multiple as those earnings arrive.

Consider one scenario: if the market decides to value those 2027 earnings at about 29.3 times, roughly halfway between today’s trailing multiple and that 12.6 times floor, the stock would be about 132% higher than it is today. A deeper look at how this valuation compares to its peers can offer additional context.

The premium you see today isn’t the price you’re really paying. On the earnings expected in two years, that same price is an ordinary multiple. Even if the stock stalls, you haven’t overpaid for the growth. If the market keeps valuing the business at anything near today’s multiple as those earnings land, the price compounds with them. To see if the story is on track, keep an eye on the operating margins within the Health Care Benefits segment, a key driver of the entire earnings forecast.

Own The Growth Without Overpaying

Whether you already hold CVS Health or you are weighing it now, the appeal is not that the stock is secretly cheap today. It is that you are not overpaying for the growth: on the earnings analysts expect two years out, you are paying an ordinary multiple, even if the price never moves.

The upside sits on top of that. If the market keeps paying anything close to today’s multiple as those earnings actually arrive, the price compounds with them. The one catch is that it all rides on a single company’s numbers coming through. And if it is exposure to U.S. healthcare providers as a whole you want rather than this one name, a U.S. healthcare providers ETF like IHF covers that single sector, though that still leaves you riding a single slice of the market. That is why the Trefis High Quality (HQ) Portfolio does not lean on any single name: it uses this same valuation-discount discipline to size a measured allocation to strong growth like this, inside a diversified set of 30 high-conviction stocks, rebalanced as the estimates change and with a track record of outpacing a benchmark that combines the three major indices – the S&P 500, S&P Mid-cap, and Russell 2000.